Nurix Therapeutics (NRIX) Gains from Investment Securities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Gains from Investment Securities data on file, last reported at $2.7 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2.7 million, changed N/A year-over-year; the trailing twelve-month figure through Feb 2026 was $35.2 million (up 270776.92% YoY), and the FY2025 annual result was $32.5 million, up 232000.0% from the prior year.
• Gains from Investment Securities slipped to $2.7 million in Q1 2026 per NRIX's latest filing, from $32.5 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $32.5 million in Q4 2025 and troughed at -$26.7 million in Q3 2025.
• A 5-year average of $3.2 million and a median of $285000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 3268.09% in 2024, then soared 10731.33% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $270000.0 in 2022, then slumped by 117.41% to -$47000.0 in 2023, then soared by 738.3% to $300000.0 in 2024, then soared by 10731.33% to $32.5 million in 2025, then plunged by 91.63% to $2.7 million in 2026.
• Business Quant data shows NRIX's Gains from Investment Securities at $2.7 million in Q1 2026, $32.5 million in Q4 2025, and -$26.7 million in Q3 2025.